IL1B and Arthritis: Neutralization of visfatin by its inhibitor (APO866) effectively reduced arthritis severity in mice with comparable activity to etanercept, and decreased pro-inflammatory cytokine (IL-1β and IL-6) secretion in affected joints [135].